NCT01323751View on ClinicalTrials.gov

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 3, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

ACY-1215

Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle

Trial Locations (6)

10029

Mt. Sinai Medical Center, New York

19104

University of Pennsylvania, Philadelphia

30322

Winship Cancer Institute, Emory University, Atlanta

53226

Medical College of Wisconsin - Clinical Cancer Center, Milwaukee

77030

MD Anderson Cancer Center, Houston

02115

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Celgene

INDUSTRY

NCT01323751 - Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma | Biotech Hunter | Biotech Hunter